IFW

Docket No.: BURNHAM.005A **Customer No. 20,995**

INFORMATION DISCLOSURE STATEMENT

Applicant	:	Tamm et al.
App. No.	:	10/665,975
Filed	:	September 18, 2003
For	:	USE OF HEPATITIS B X-INTERACTING PROTEIN (HBXIP) IN MODULATION OF APOPTOSIS
Examiner	:	Unknown
Group Art Unit	:	1648

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 31 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 26, 2004

By: _____

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

O:\DOCS\MXG\MXG-5792.DOC:vr
082304

PATENT

Case Docket No. BURNHAM.005A
Date: August 26, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Tamm et al.
Appl. No.	:	10/665,975
Filed	:	September 18, 2003
For	:	USE OF HEPATITIS B X-INTERACTING PROTEIN (HBXIP) IN MODULATION OF APOPTOSIS
Examiner	:	Unknown
Group Art Unit	:	1648

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 26, 2004
(Date)

Marina L. Gordey, Reg. No. 52,950

TRANSMITTAL LETTER

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with thirty-one (31) references.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

O:\DOCS\MXG\MXG-5793.DOC:vr
082304

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. BURNHAM.005A	APPLICATION NO. 10/665,975
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Tamm et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE September 18, 2003	GROUP 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1.	Ambrosini, G. et al. "A novel anti-apoptosis gene, *survivin*, expressed in cancer and lymphoma." *Nature Med* **3**:917-921 (1997).
	2.	Banks, D.P. et al. "Survivin does not inhibit caspase-3 activity." *Blood* **96**:4002-4003 (2000).
	3.	Bratton, S.B. et al. "Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes."*EMBO J* **20**:998-1009 (2001).
	4.	Cryns, V. et al. "Proteases to die for."*Genes Dev* **12**:1551-1570 (1998).
	5.	Deveraux, Q.L. et al. "IAP family proteins: Suppressors of apoptosis."*Genes Dev* **13**:239-252 (1999).
	6.	Deveraux, Q.L. et al. "X-linked IAP is a direct inhibitor of cell death proteases." *Nature* **388**:300-304 (1997).
	7.	Gottlob, K. et al. "The Hepatitis B virus HBx protein inhibits caspase 3 activity."*J Biol Chem* **273**:33347-33353 (1998).
	8.	Grossman, D. et al. "Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53."*J Clin.Invest* **108**:991-999 (2001).
	9.	Kim, C.M. et al. "HBx gene of hepatitis B virus induces liver cancer in transgenic mice."*Nature* **351**:317-320 (1991).
	10.	Li, F. et al. "Control of apoptosis and mitotic spindle checkpoint by survivin." *Nature* **396**:580-584 (1998).
	11.	Li, P. et al. "Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade." *Cell* **91**:479-489 (1997).
	12.	Lok, A.S. "Hepatitis B infection: Pathogenesis and management." *J Hepatol* **32**:89-97 (2000).
	13.	Marusawa, H. et al. "HBXIP functions as a cofactor of survivin in apoptosis suppression" *The EMBO J.* **22**:2729-2740 (2003)
	14.	Marusawa, H. et al. "Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen." *Hepatology* **31**:488-495 (2000).
	15.	Matsuzawa, S. et al. "Siah-1, SIP, and Ebi collaborate in a novel pathway for -catenin degradation linked to p53 responses." *Mol Cell* **7**:915-926 (2001).
	16.	Melegari, M. et al. "Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication." *J Virol* **72**:1737-1743 (1998).

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.	APPLICATION NO.
BURNHAM.005A	10/665,975
APPLICANT: Tamm et al.	
FILING DATE: September 18, 2003	GROUP: 1648

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	17.	Murakami, S. "Hepatitis B virus X protein: A multifunctional viral regulator." *J Gastroenterol* **36**:651-660 (2001).
	18.	O'Connor, D.S. et al. "Regulation of apoptosis at cell division by $p34^{cdc2}$ phosphorylation of survivin." *PNAS USA* **97**:13103-13107 (2000).
	19.	Reed, J.C. et al. "BIRinging chromosomes through cell division - and survivin the experience." *Cell* **102**: 545-548 (2000).
	20.	Reed, J.C. "The survivin saga goes in vivo." *J Clin Invest* **108**:965-969 (2001).
	21.	Riedl, S.J. et al. "Structural basis for the inhibition of caspase-3 by XIAP." *Cell* **104**:791-800 (2001).
	22.	Salvesen, G.S. "Caspases: opening the boxes and interpreting the arrows." *Cell Death Differ* **9**:3-5 (2002).
	23.	Shin, S. et al. "An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7." *Biochem* **40**: 1117-1123 (2001).
	24.	Stennicke, H.R. et al. "Caspase-9 can be activated without proteolytic processing." *J Biol Chem* **274**:8359-8362 (1999).
	25.	Sun, C. et al. "NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP." *Nature* **401**:818-822 (1999).
	26.	Tamm, I. et al. "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs." *Cancer Res* **58**:5315-5320 (1998).
	27.	Velculescu, V.E. et al. "Analysis of human transcriptomes." *Nature Gen* **23**:387-388 (1999).
	28.	Verdecia, M.A. et al. "Structure of the Human anti-apoptotic protein survivin reveals a dimeric arrangement." *Nature Struct Biol* **7**:602-608 (2000).
	29.	Yang, J. et al. "Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked." *Science* **275**: 1129-1132 (1997).
	30.	Zhou, Q. et al. "Target protease specificity of the viral serpin CrmA: analysis of five caspases." *J Biol Chem* **272**: 7797-7800 (1997)
	31.	Zou, H. et al. "An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9." *J Biol Chem* **274**:11549-11556 (1999).

O:\DOCS\MXG\MXG-5079.DOC:vr
042904

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.